Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

12 juin 2019 mis à jour par: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Aperçu de l'étude

Statut

Résilié

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

876

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Chine
      • Beijing, Chine, 100050
        • Novartis Investigative Site
      • Chongqing, Chine, 400037
        • Novartis Investigative Site
      • Shanghai City, Chine
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, Chine, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, Chine, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, Chine, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Chine, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, Chine, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, Chine, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, Chine
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, Chine, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, Chine, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, Chine, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, Chine, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Chine, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, Chine, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Chine, 325000
        • Novartis Investigative Site
  • Corée, République de
      • Busan, Corée, République de, 602739
        • Novartis Investigative Site
      • Gwangju, Corée, République de, 61469
        • Novartis Investigative Site
      • Incheon, Corée, République de, 405 760
        • Novartis Investigative Site
      • Seoul, Corée, République de, 03080
        • Novartis Investigative Site
      • Seoul, Corée, République de, 03722
        • Novartis Investigative Site
      • Seoul, Corée, République de, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, Corée, République de, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, Corée, République de, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, Corée, République de, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, Corée, République de, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Corée, République de, 05505
        • Novartis Investigative Site
      • Seoul, Korea, Corée, République de, 06351
        • Novartis Investigative Site
      • Seoul, Korea, Corée, République de, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, Corée, République de, 06591
        • Novartis Investigative Site
  • Inde
      • Rajasthan, Inde, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, Inde, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Inde, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, Inde, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, Inde, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Inde, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, Inde, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Inde, 500082
        • Novartis Investigative Site
  • Japon
      • Osaka, Japon, 534-0021
        • Novartis Investigative Site
      • Saitama, Japon, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, Japon, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, Japon, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, Japon, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, Japon, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, Japon, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, Japon, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japon, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japon, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, Japon, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japon, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japon, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, Japon, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, Japon, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Japon, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, Japon, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, Japon, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, Japon, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, Japon, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, Japon, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, Japon, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, Japon, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, Japon, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japon, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japon, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japon, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, Japon, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, Japon, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, Japon, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, Japon, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, Japon, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, Japon, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, Japon, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, Japon, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, Japon, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, Japon, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, Japon, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, Japon, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, Japon, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, Japon, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, Japon, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, Japon, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, Japon, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, Japon, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, Japon, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, Japon, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Japon, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, Japon, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, Japon, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, Japon, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, Japon, 646-8558
        • Novartis Investigative Site
  • Jordan
      • Amman, Jordan, 11183
        • Novartis Investigative Site
      • Amman, Jordan, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, Jordan, 11152
        • Novartis Investigative Site
  • Liban
      • Ashrafieh, Liban, 166830
        • Novartis Investigative Site
      • Beirut, Liban, 1107 2020
        • Novartis Investigative Site
      • Beirut, Liban
        • Novartis Investigative Site
      • Hazmieh, Liban, 470
        • Novartis Investigative Site
  • Malaisie
      • Kuala Lumpur, Malaisie, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, Malaisie, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, Malaisie, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, Malaisie, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malaisie, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, Malaisie, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, Malaisie, 47000
        • Novartis Investigative Site
  • Philippines
      • Makati City, Philippines, 1229
        • Novartis Investigative Site
      • Manila, Philippines, 1003
        • Novartis Investigative Site
      • Pasig City, Philippines, 1605
        • Novartis Investigative Site
      • Quezon City, Philippines, 1102
        • Novartis Investigative Site
      • Quezon City, Philippines, 1113
        • Novartis Investigative Site
      • San Juan City, Philippines, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, Philippines, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Philippines, 1000
        • Novartis Investigative Site
  • Singapour
      • Singapore, Singapour, 169609
        • Novartis Investigative Site
      • Singapore, Singapour, 117549
        • Novartis Investigative Site
  • Taïwan
      • Changhua, Taïwan, 50006
        • Novartis Investigative Site
      • Kaohsiung, Taïwan, 80756
        • Novartis Investigative Site
      • Kaohsiung City, Taïwan, 83301
        • Novartis Investigative Site
      • New Taipei, Taïwan, 22060
        • Novartis Investigative Site
      • Taichung, Taïwan, 40447
        • Novartis Investigative Site
      • Taipei, Taïwan, 10002
        • Novartis Investigative Site
      • Taipei, Taïwan, 11217
        • Novartis Investigative Site
      • Taipei, Taïwan, 10449
        • Novartis Investigative Site
      • Taoyuan, Taïwan, 33305
        • Novartis Investigative Site
      • Yilan, Taïwan, 26058
        • Novartis Investigative Site
  • Thaïlande
      • Bangkok, Thaïlande, 10330
        • Novartis Investigative Site
      • Bangkok, Thaïlande, 10700
        • Novartis Investigative Site
      • Bangkok, Thaïlande, 10400
        • Novartis Investigative Site
      • Chiang Mai, Thaïlande, 50200
        • Novartis Investigative Site
      • Muang, Thaïlande, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Thaïlande, 90110
        • Novartis Investigative Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Médicament: Placebo
Perfusion intraveineuse
Autre: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Expérimental: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
Autre: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Médicament: Sérélaxine
Perfusion intraveineuse

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
Délai: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Time to WHF
Délai: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
Délai: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
Délai: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
Délai: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
Délai: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
Délai: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
Délai: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
Délai: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
Délai: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
Délai: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
Délai: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
Délai: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
Délai: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Novartis Pharmaceuticals

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

12 mars 2014

Achèvement primaire (Réel)

27 mars 2017

Achèvement de l'étude (Réel)

16 juin 2017

Dates d'inscription aux études

Première soumission

20 novembre 2013

Première soumission répondant aux critères de contrôle qualité

9 décembre 2013

Première publication (Estimation)

11 décembre 2013

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 août 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 juin 2019

Dernière vérification

1 juin 2019

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • CRLX030A2302

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Insuffisance cardiaque aiguë

Essais cliniques sur Placebo

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in South Korea

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner